Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations: 2021-2025

Historic Cash from Operations for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.6 million.

  • InMed Pharmaceuticals' Cash from Operations rose 12.00% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 13.70%. This contributed to the annual value of -$7.8 million for FY2025, which is 11.18% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cash from Operations of -$1.6 million as of Q3 2025, which was up 9.61% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Cash from Operations high stood at -$657,934 for Q2 2023, and its period low was -$5.3 million during Q1 2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Cash from Operations value was -$1.8 million (recorded in 2025), while the average stood at -$1.7 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Cash from Operations skyrocketed by 83.74% in 2023 and then tumbled by 72.81% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Cash from Operations stood at -$3.5 million in 2021, then grew by 23.22% to -$2.7 million in 2022, then spiked by 31.88% to -$1.8 million in 2023, then tumbled by 35.39% to -$2.5 million in 2024, then grew by 12.00% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, -$1.8 million for Q2 2025, and -$1.7 million during Q1 2025.